Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus lenvatinib or sorafenib versus lenvatinib or sorafenib alone after prior atezolizumab + bevacizumab in advanced hepatocellular carcinoma
MOH_2021-07-05_009806Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atezolizumab, lenvatinib and sorafenib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Roche. Planned start May 2021; status: not yet recruiting.
02
Drugs
atezolizumablenvatinibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on MOH_2021-07-05_009806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-07-05_009806.